Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT6026 in advanced solid tumors
NCT05105971Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT6026 in solid tumor (advanced stage) (8 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-Limiting Toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Started Dec 2021; status: completed.
02
Drugs
BAT6026
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05105971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105971.